Ritalin Abuse and its Complications

Document Type : Review Article

Authors

1 Student, Department of Psychology, School of Psychology and Educational Sciences, Allameh Tabataba'i University, Tehran, Iran

2 Student, Farzanegan Gifted-Scholars High School-1, Tehran, Iran

3 Assistant Professor, Cellular and Molecular Research Center AND Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

4 Assistant Professor, Cellular and Molecular Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

5 PhD Student, Department of Psychology, School of Psychology and Educational Sciences, Allameh Tabataba'i University, Tehran, Iran

6 Associate Professor, Cellular and Molecular Research Center AND Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Ritalin is a methylphenidate and a stimulant of the nervous system. Its Pharmacological effects are similar to amphetamines. Ritalin is used in hyperactive children and in some cases of brain trauma usually in the form of tablets. It has been the most effective and common drug for treatment of attention-deficit hyperactivity disorder (ADHD) for years. Ritalin has a high potential for abuse, particularly in some students use it to increase focus in order to success in exams. Use of high-dose Ritalin via intravenous and inhalation or intranasal administration can cause many complications similar to cocaine and amphetamine. These complications include violent behavior, hallucinations, hyperexcitability, irritability, panic, and psychosis. In some animal models, structural damage to the nervous system and other organs has been reported. So, distribution and usage of Ritalin should accurately be controlled and monitored to prevent its abuse.

Keywords

References

  1. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75(7): 711-21.
  2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51(1): 8-19.
  3. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed. Washington, DC: APA; 2000. p. 85-103.
  4. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279(14): 1100-7.
  5. Findling RL, Dogin JW. Psychopharmacology of ADHD: children and adolescents. J Clin Psychiatry 1998; 59(Suppl 7): 42-9.
  6. Firestone P, Musten LM, Pisterman S, Mercer J, Bennett S. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1998; 8(1): 13-25.
  7. Morton WA, Stockton GG. Methylphenidate Abuse and Psychiatric Side Effects. Prim Care Companion J Clin Psychiatry 2000; 2(5): 159-64.
  8. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87(1): 20-9.
  9. Nupponen I. Phagocyte Activation as an Indicator of Systemic Inflammation in the Newborn Infant [Dissertation]. Helsinki, Finland: University of Helsinki; 2002.
  10. Rafiq A, Shah A. Stimulant-induced psychosis: importance of patient education and compliance. Prim Care Companion CNS Disord 2013; 15(6).
  11. Dafny N, Yang PB. The role of age, genotype, sex, and route of acute and chronic administration of methylphenidate: a review of its locomotor effects. Brain Res Bull 2006; 68(6): 393-405.
  12. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283(8): 1025-30.
  13. Wenthur CJ. Classics in Chemical Neuroscience: Methylphenidate. ACS Chem Neurosci 2016; 7(8): 1030-40.
  14. Kermanian F, Mehdizadeh M, Soleimani M, Ebrahimzadeh Bideskan AR, Asadi-Shekaari M, Kheradmand H, et al. The role of adenosine receptor agonist and antagonist on Hippocampal MDMA detrimental effects; a structural and behavioral study. Metab Brain Dis 2012; 27(4): 459-69.
  15. Soleimani M, Katebi M, Alizadeh A, Mohammadzadeh F, Mehdizadeh M. The Role of The A2A Receptor in Cell Apoptosis Caused by MDMA. Cell J 2012; 14(3): 231-6.
  16. Soleimani AS, Mousavizadeh K, Pourheydar B, Soleimani M, Rahbar E, Mehdizadeh M. Protective effects of N-acetylcysteine on 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in male Sprague-Dawley rats. Metab Brain Dis 2013; 28(4): 677-86.
  17. Movassaghi S, Nadia SZ, Mohammadzadeh F, Soleimani M. Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy). Iran J Basic Med Sci 2013; 16(8): 922-7.
  18. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, et al. Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 1999; 156(1): 19-26.
  19. Konstenius M, Jayaram-Lindstrom N, Beck O, Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010; 108(1-2): 130-3.
  20. Meltzer HY. Psychopharmacology: The third generation of progress. New York, NY: Raven Press; 1987.
  21. Volkow ND, Wang GJ, Gatley SJ, Fowler JS, Ding YS, Logan J, et al. Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology (Berl) 1996; 123(1): 26-33.
  22. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley JS, et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 1995; 52(6): 456-63.
  23. Levine B, Caplan YH, Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986; 10(5): 209-10.
  24. US Department of Justice. Drug Enforcement Administration Report on Methylphenidate (Ritalin). Washington, DC: Office of Diversion Control, Drug and Chemical Evaluation Section; 1995.
  25. Fazelipour S, Tootian Z, Mohammadzadeh Kazergah F, Kiaie B, Chegini HR, Mohammadzadeh Kazergah A, et al. Effect of methylphenidate hydrochloride on ovarian and pituitary gonadotropin hormone in peripubertal mice. J Gorgan Uni Med Sci 2013; 15(1): 12-18. [In Persian].
  26. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011; 306(24): 2673-83.
  27. Cherland E, Fitzpatrick R. Psychotic side effects of psychostimulants: a 5-year review. Can J Psychiatry 1999; 44(8): 811-3.
  28. Adler LA, Spencer T, McGough JJ, Jiang H, Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord 2009; 12(5): 449-59.
  29. Outram SM. The use of methylphenidate among students: the future of enhancement? J Med Ethics 2010; 36(4): 198-202.
  30. Brunton L, Chabner B, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill; 2011.
  31. Jaffe SL. Intranasal abuse of prescribed methylphenidate by an alcohol and drug abusing adolescent with ADHD. J Am Acad Child Adolesc Psychiatry 1991; 30(5): 773-5.
  32. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000; 283(13): 1710-4.
  33. Musser CJ, Ahmann PA, Theye FW, Mundt P, Broste SK, Mueller-Rizner N. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J Dev Behav Pediatr 1998; 19(3): 187-92.
  34. Fowler JS, Volkow ND. PET imaging studies in drug abuse. J Toxicol Clin Toxicol 1998; 36(3): 163-74.
  35. McCormick, Jr, T, McNeel TW. Acute psychosis and Ritalin abuse. Tex State J Med 1963; 59: 99-100.
  36. Spensley J, Rockwell DA. Psychosis during methylphenidate abuse. N Engl J Med 1972; 286(16): 880-1.
  37. Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002; 14(2): 219-23.
  38. Porfirio MC, Giana G, Giovinazzo S, Curatolo P. Methylphenidate-induced visual hallucinations. Neuropediatrics 2011; 42(1): 30-1.
  39. Lewman LV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol 1972; 3(1): 67-70.
  40. Parran TV, Jr., Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991; 151(4): 781-3.
  41. McDonald BC, Flashman LA, Arciniegas DB, Ferguson RJ, Xing L, Harezlak J, et al. Methylphenidate and Memory and Attention Adaptation Training for Persistent Cognitive Symptoms after Traumatic Brain Injury: A Randomized, Placebo-Controlled Trial. Neuropsychopharmacology 2017.
  42. Schweren LJ, de ZP, Durston S. MR imaging of the effects of methylphenidate on brain structure and function in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol 2013; 23(10): 1151-64.
  43. Comim CM, Gomes KM, Reus GZ, Petronilho F, Ferreira GK, Streck EL, et al. Methylphenidate treatment causes oxidative stress and alters energetic metabolism in an animal model of attention-deficit hyperactivity disorder. Acta Neuropsychiatr 2014; 26(2): 96-103.
  44. Kroft C, Cole JO. Adverse behavioral effects of psychostimulants, in Adverse Effects of Psychotropic Drugs. Kane JM, Lieberman JA, editors. New York, NY; 1992. p. 153–62.
  45. Segal D, Janowsky D. Psychostimulant-induced behavioral effects: possible models of schizophrenia. In: Lipton, MA, Di Mascio A, Killam KF, editors. Psychopharmacology: A generation of progress. New York, NY: Raven Press; 1978. p. 1113-23.
  46. Volavka J. Neurobiology of Violence. Washington, DC: American Psychiatric Publishing; 2008.
  47. Maksimowski MB, Tampi RR. Efficacy of stimulants for psychiatric symptoms in individuals with traumatic brain injury. Ann Clin Psychiatry 2016; 28(3): 156-66.
  48. Bramness JG, Gundersen OH, Guterstam J, Rognli EB, Konstenius M, Loberg EM, et al. Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry 2012; 12: 221.
  49. Mahmoudi M, Abedi A, Shafie E, Yarmohamadyan A, Karamimanesh V, Fatemi A. Comparing the neuropsychological features in preschool children with and without developmental coordination disorder (DCD). J Isfahan Med Sch 2014; 31(265): 2063-80. [In Persian].
  50. Schuckit MA. Drug and alcohol abuse: A clinical guide to diagnosis and treatment. New York, NY: Springer; 2006.
  51. Karapinar U, Saglam O, Dursun E, Cetin B, Salman N, Sahan M. Sudden hearing loss associated with methylphenidate therapy. Eur Arch Otorhinolaryngol 2014; 271(1): 199-201.
  52. Rappley MD. Safety issues in the use of methylphenidate. An American perspective. Drug Saf 1997; 17(3): 143-8.
  53. American Hospital Formulary Service. AHFS Drug Information 2013. Bethesda, MD: American Society of Health-System Pharmacists; 2012.
  54. Wender PH. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 1998; 59(Suppl 7): 76-9.
Journal of Isfahan Medical School
Volume 35, Issue 420 - Serial Number 420
January and February 2017
Pages 170-176

Files

History

  • Receive Date: 16 January 2017
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics